


Substitute for form 1449/PTO, based on PTO/SB/08A and 08B INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/680,076
	Filing Date	October 6, 2003
	First Named Inventor	Bell et al.
	Art Unit	1614 1624
	Examiner Name	Not assigned COLEMAN
	Attorney Docket Number	36-02



U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	class	subclass
BC		6,342,492	01/29/02	Bell	514	183	
BC		6,335,339	01/01/02	Arenas et al.	514	245	
BC		5,663,161	09/02/97	Bell	514	183	
BC		5,565,562	10/15/96	Parker et al.	540	465	
BC		2002/0019423	02/14/02	Bell	514	360	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²
BC		WO96/025167	08/22/96			
BC		JP 08-27129	01/30/96			

**

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC		Bell, T.W. et al. (March 2002), "Specific CD4 Down-modulating Compounds with Potent Anti-HIV and HHV-7 Activity," Abstract, 15 th Intl. Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002	
BC		Chieco-Bianchi, L. et al. (1989), "CD4 modulation and inhibition of HIV-1 infectivity induced by monosialoganglioside GM1 in vitro," AIDS 3:501-507	
BC		Chowdhury, I.H. et al. (1990), "The Phorbol Ester TPA Strongly Inhibits HIV-1-induced Syncytia Formation but Enhances Virus Production: Possible Involvement of Protein Kinase C Pathway," Virology 176:126-132	
BC		Hoffman, T.L. et al. (1990), "Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein," Proc. Natl. Acad. Sci. USA 96:6359-6364	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2006
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

** Structures only

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/680,076
Filing Date	October 6, 2003
First Named Inventor	Bell et al.
Art Unit	4644 1624
Examiner Name	Not assigned COLEMAN
Attorney Docket Number	36-02

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC		Kabat, D. et al. (1994), "Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1," J. Virol. 68:2570-2577	
BC		Kolchinski, P. et al. (March 2001), "Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants," J. Virol. 75:2041-2050	
BC		Layne, S.P. et al. (1990), "HIV requires multiple gp120 molecules for CD4 mediated infection," Nature 346:277-279	
BC		Neudorf, S. et al. (1989), "Expression of the CD4 Molecule of Acute Nonlymphocytic Leukemia (ANLL) Cell Lines," J. Clin. Lab. Anal. 3:312-315	
BC		Platt, E.J. et al. (1997), "Infectious Properties of Human Immunodeficiency Virus Type 1 Mutants with Distinct Affinities for the CD4 Receptor," J. Virol. 61:883-890	
BC		Schols, D. et al. (1989), "Specific interaction of aurointricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor," Proc. Natl. Acad. Sci. USA 86:3322-3326	
BC		Vermeire, K. et al. (January 2003), "The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor," Mol. Pharmacol. 63:203-210	
BC		Vermeire, K. et al. (October 2002), "CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor," Virology 302: 342-353	
BC		Zhang, Y. et al. (1999), "Selective activity of various antiviral compounds against HHV-7 infection," Antiviral Res. 43:23-35	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2006
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10680076	
	Filing Date		2003-10-06	
	First Named Inventor	Thomas Bell		
	Art Unit		1624	
	Examiner Name	COLEMAN, Brenda Libby		
	Attorney Docket Number		36-02	

U.S. PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.								
U.S. PATENT APPLICATION PUBLICATIONS								
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.								
FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button								
NON-PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10680076
	Filing Date	2003-10-06
	First Named Inventor	Thomas Bell
	Art Unit	1624
	Examiner Name	COLEMAN, Brenda Libby
	Attorney Docket Number	36-02

BC ¹	BELL, T.W., et al., Synthesis and Structure - Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (DADA) Analogues, J. Med. Chem. 2006, 49, 1291-1312. Published on Web 02/02/2006.	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button		
EXAMINER SIGNATURE		
Examiner Signature	Brenda Coleman	Date Considered Sept. 29, 2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>		